Telehealth Growth Desk: Tirzepatide Shortage Over, Now What?

On December 19, 2024, the FDA issued an order noting the resolution of the tirzepatide shortage, covering Mounjaro and Zepbound.² It was the second time it had reached that conclusion in about two and a half months. For clinics whose offer leans on compounded tirzepatide, the clock matters more than the headline. The shortage that made compounding possible is over, and the wind-down has dates.

Dates make this one easier than most regulatory stories. There is a decision, a window and two deadlines. The decision is already made.

Telehealth Growth Desk covers the news that changes how clinics grow. This is education about public information, not legal advice. Check your own arrangements with a healthcare attorney and your pharmacy partners.

What did the FDA decide on December 19?

It re-confirmed an earlier decision, after a court-ordered pause.

The short history

The FDA first said on October 2, 2024 that the tirzepatide shortage had been resolved. Its statement noted that compounded drugs are not FDA-approved and must meet conditions under section 503A or 503B, and that once a shortage is resolved the FDA generally considers a drug to be commercially available under 503A, while 503B outsourcing facilities cannot make drugs that are essentially copies of an approved drug unless it is on the shortage list.¹

Then the story paused. The FDA's page records that on October 22 the shortage-list removal was sent back for reevaluation, and that on December 19 the agency reevaluated and again determined the shortage resolved.¹ A summary of the order notes that groups representing outsourcing facilities had sued, calling the original decision arbitrary.²

What the order says about supply

The shortage is described as having begun in December 2022. The summary of the order says the resolution comes with potential localized disruptions due to supply chain dynamics.²

What are the dates on the wind-down?

Two windows, two deadlines.

How to read the windows

The summary describes both as enforcement discretion windows, which means a limited period and not a permanent allowance.² They are not permission to expand. A window to wind down is a different thing from a green light.

Why the dates could still move

Groups representing compounders have already challenged this decision once in court, and the FDA paused and then reaffirmed it.² Treat the dates as the current public timeline, ask your pharmacy partner what they are doing and plan for the dates holding.

STAT's explainer, published November 26, 2024, states the rule behind all of this plainly: "Compounders must cease production of these drugs as soon as they come off the FDA shortage list."⁵ The sentence sounds simple until a listing is reversed days after it changes, which STAT describes happening with tirzepatide in October 2024. That is why I treat the FDA's own pages as the source of record.

Plays here, from YouTube

What does "essentially a copy" mean for your clinic?

That is a question for your attorney and pharmacist, not for a marketing blog.

Questions to put to your partners

• Which of our current prescriptions rely on a compounded version of tirzepatide?
• Under which provision, 503A or 503B, does our pharmacy partner operate for these products?
• What is their plan and date for winding down, and how will they notify patients and prescribers?
• Is there a documented clinical reason for any individualized preparation, and who decides that?

Get the answers in writing. If your pharmacy partner is vague, treat that as information.

How do you rebuild the offer?

Around the part that does not expire.

What the customer is really paying for

A telehealth weight program is more than a drug. It is clinical assessment, prescribing decisions, monitoring, follow-up, and the support that keeps a patient engaged. Those pieces keep their value whatever the product in the syringe, and they are exactly what keeps patients past month three (see GLP-1 patient retention). If your page and your ads sell the compounded product as the main attraction, the whole message has to change.

A rebuilt offer, in four moves

If you offer brand-name tirzepatide, Lilly's release describes single-dose Zepbound vials available for self-pay through its LillyDirect channel with a valid, on-label prescription, priced at the time of that release at $399 for a four-week supply of 2.5 mg and $549 for 5 mg.³ Check current pricing and terms before you use any number in your own materials. Those figures are from August.

A rule for the next 90 days

Watch label news

The same day as the FDA order, the agency approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, which it described as the first drug treatment option for certain patients with the condition.⁴ Label changes alter who is eligible and how conditions can be discussed. Have your clinical leadership decide how that fits your practice before your marketing says anything about it.

What should your marketing do now?

Clean up, slow down and stay accurate.

Review the claims

Any ad or page that names a drug, compares compounded and brand versions, or implies a supply situation needs review by counsel before it runs (start with what clinics can and cannot claim). I would also remove any claim that depends on the shortage still existing. Ad platforms apply their own health and wellness policies, and Meta has told advertisers about new restrictions on health data events (see Meta Is Coming for Health Data).

Tell patients early

If your patients rely on a compounded product, tell them what is changing and when, before the deadline. Patients forgive a clear, early message. They do not forgive a surprise.

Every category I have seen has had a moment where the thing the market loved changed. The operators who survived had sold the relationship and the result, not the ingredient. If you want to talk through how to rebuild your offer around that, start at my telehealth page.

Keep building.Ekai